Proactiveinvestors Australia

Benitec Biopharma www.benitec.com/

Benitec Biopharma (ASX: BLT) is investigating long term gene silencing using DNA-directed RNA interference (ddRNAi) for human therapeutics. The company’s primary therapeutic program focuses on human immunodeficiency virus (HIV). Its other projects are in the area of infectious diseases and cancer.

Pdf

Benitec Biopharma acquires U.S. based Tacere Therapeutics

Tuesday, October 30, 2012 by Angela Kean

Benitec Biopharma acquires U.S. based Tacere Therapeutics

Benitec Biopharma (ASX: BLT) has completed the acquisition of U.S.-based RNA interference (RNAi) therapeutics company Tacere Therapeutics, providing Benitec with an advanced preclinical asset.

With the acquisition complete, Benitec has the opportunity to enter the clinic in mid-2013 with Tacere’s Phase I/IIa ready therapeutic program in hepatitis C that use Benitec’s novel gene silencing technology, ddRNAi.

The pre-clinical data and safety profile of TT-034 positions Benitec to begin clinical trials in hepatitis C at a time when a number of high profile HCV therapies are encountering safety concerns.

Importantly, successful Phase II clinical data is a key driver to securing deals with major pharmaceutical companies.

The worldwide market for new hepatitis C treatments is projected to reach $20 billion by 2020.

Hepatitis C virus (HCV) infection is a leading cause of liver disease worldwide, with no known cure apart from liver transplantation.

The World Health Organisation estimates around 170 million people are chronically infected, with 350,000 deaths from HCV-related liver disease each year.

Tacere has also been conducting extensive preclinical work in the area of macular degeneration, with promising early results.

The company has been successfully developing programs utilising Benitec's proprietary ddRNAi technology since 2006.


Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.

Sign up to Proactive Investors

Andrew McCrea's Research Reports
Sign up to Andrew McCrea's Research Reports and Receive Latest Research & Flash Trades
Receive Proactive Investors Newsletter, Investor Forum Invites
Receive Proactive Investors Newsletter, Event Invites, Special Stock Notifications

Comments from Proactive Investors readers

  • Fill in your details below:
Verification Code
Andrew McCrea is Sub Authorised Representative (SAR: 291331) of Proactive Investors Australia Pty Ltd
(ABN: 19 132 787 654) which is a Corporate Auhorised Representative (CAR: 413802) of RM Capital
Pty Ltd (AFSL: 221938).

Copyright © proactiveinvestors.com.au, 2012. All Rights Reserved